1,021
Views
20
CrossRef citations to date
0
Altmetric
Original Article

The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase NEDD4-1

, , , , , & show all
Pages 39-45 | Received 27 Nov 2014, Accepted 20 Jan 2015, Published online: 26 May 2015

References

  • Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722
  • Anan T, Nagata Y, Koga H, Honda Y, Yabuki N, Miyamoto C, et al. 1998. Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. Genes to Cells 3:751–763
  • Barsnes H, Vaudel M, Colaert N, Helsens K, Sickmann A, Berven FS, Martens L. 2011. compomics-utilities: an open-source Java library for computational proteomics. BMC Bioinformatics 12:70
  • Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Investigation 115:3285–3290
  • Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333–344
  • Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, et al. 2000. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Human Molec Genetics 9:1209–1217
  • Fu D, Roufogalis BD. 2007. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol Cell Physiol 292:C1543–C1552
  • Hartz AM, Miller DS, Bauer B. 2010. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Molec Pharmacol 77:715–723
  • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99–102
  • Ingham RJ, Gish G, Pawson T. 2004. The Nedd4 family of E3 ubiquitin ligases: Functional diversity within a common modular architecture. Oncogene 23:1972–1984
  • Jeynes B, Provias J. 2011. An investigation into the role of P-glycoprotein in Alzheimer’s disease lesion pathogenesis. Neurosci Lett 487:389–393
  • Karlnoski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, et al. 2009. Suppression of amyloid deposition leads to long-term reductions in Alzheimer’s pathologies in Tg2576 mice. J Neurosci 29:4964–4971
  • Katayama K, Noguchi K, Sugimoto Y. 2013. FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells. Cancer Sci 104:694–702
  • Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. 2007. MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides – implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17:347–353
  • Martin CA, Longman E, Wooding C, Hoosdally SJ, Ali S, Aitman TJ, et al. 2007. Cd36, a class B scavenger receptor, functions as a monomer to bind acetylated and oxidized low-density lipoproteins. Protein Sci 16:2531–2541
  • Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, et al. 1989. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biolog Chem 264:18031–18040
  • Muller C, Laurent G, Ling V. 1995. P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cellular Physiol 163:538–544
  • Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I. 1988. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 27:7607–7613
  • Ritchie TK, Grinkova YV, Bayburt TH, Denisov IG, Zolnerciks JK, Atkins WM, Sligar SG. 2009. Chapter 11: Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Meth Enzymol 464:211–231
  • Rotin D, Kumar S. 2009. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 10:398–409
  • Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. 1995. Characterization of a novel protein-binding module – the WW domain. FEBS Lett 369:67–71
  • Sudol M, Hunter T. 2000. NeW wrinkles for an old domain. Cell 103:1001–1004
  • Sullivan JA, Lewis MJ, Nikko E, Pelham HR. 2007. Multiple interactions drive adaptor-mediated recruitment of the ubiquitin ligase rsp5 to membrane proteins in vivo and in vitro. Molecul Biol Cell 18:2429–2440
  • Taylor AM, Storm J, Soceneantu L, Linton KJ, Gabriel M, Martin C, et al. 2001. Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br J Pharmacol 134:1609–1618
  • Vaudel M, Barsnes H, Berven FS, Sickmann A, Martens L. 2011. SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. Proteomics 11:996–999
  • Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, et al. 2002. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535–541
  • Yoshimura A, Kuwazuru Y, Sumizawa T, Ikeda S, Ichikawa M, Usagawa T, Akiyama S. 1989. Biosynthesis, processing and half-life of P-glycoprotein in a human multidrug-resistant KB cell. Biochim et Biophys Acta 992:307–314
  • Zhang Z, Wu JY, Hait WN, Yang JM. 2004. Regulation of the stability of P-glycoprotein by ubiquitination. Molec Pharmacol 66:395–403
  • Zlokovic BV. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201
  • Zolnerciks JK, Akkaya BG, Snippe M, Chiba P, Seelig A, Linton KJ. 2014. The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle. FASEB J 28:4335–4346
  • Zolnerciks JK, Wooding C, Linton KJ. 2007. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J 21:3937–3948

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.